Metal complexes

A method for agonizing the G-CSF receptor in a subject in need thereof which comprises administering to the subject a therapeutically effective amount of a G-CSF receptor binding moiety;

• except compounds of the formula:
• wherein R1, R2, R3 and R4 are independently aryl, where aryl is cyclic or polycyclic aromatic C3-C12, optionally containing one or more heteroatoms, provided that when C is 3 the aromatic ring contains at least two heteroatoms, and when C is 4 the aromatic ring contains at least one heteroatom, and optionally substituted with one or more substituents selected from the group consisting of:
• C(O)NR6R7 and NR6R7, aryloxy, cycloalkyl, substituted cycloalkyl, akyl, C6-C12aryl, alkoxy, acyloxy, substituted C6-C12aryl, amino, N-acylamino, nitro, cyano, halogen, hydroxy, —C(O)OR6, —S(O)nR5, protected —OH and alkyl substituted with one or more substituents selected from the group consisting of:
• alkoxy, acyloxy, C6-C2aryl, substituted C6-C12aryl, amino, N-acylano, oxo, hydroxy, cycloalkyl, substituted cycloalkyl, —C(O)OR6, —S(O)nR7, aryloxy, nitro, cyano, halogen and protected —OH, where
• R6 is hydrogen or alkyl,
• n is 0-2,
• R7 is hydrogen or alkyl and
• R5 is hydrogen, cycloalkyl, C6-C12aryl substituted cycloalkyl, substituted C6-C12aryl, alkyl or alkyl substituted with one or more substituents selected from the group consisting of:
• alkoxy, acyloxy, aryloxy, amino, N-acylamino, oxo, hydroxy, —C(O)OR6, —S(O)nR7, nitro, cyano, cycloalkyl, substituted cycloalkyl, halogen, C6-C12aryl, substituted C6-C12aryl and protected —OH, where R6 is hydrogen or alkyl, n is 0-2 and R7 is hydrogen or alkyl;
• or a pharmaceutically acceptable salt, hydrate, solvate or ester thereof.